More on Bristol-Myers (BMY -2.5%) Q3: swings to net loss of $711M from $969M last year, due to...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

More on Bristol-Myers (BMY -2.5%) Q3: swings to net loss of $711M from $969M last year, due to $1.8B charge for failed hepatitis C treatment. Earnings also hurt by Plavix sales plunging 96% to $64M following loss of patent protection, with sales of Avapro hit for the same reason. Guides to upper end of EPS 2012 forecast of $1.90-$2 vs. consensus of $1.92. Revenue seen at $17.4B-$17.8B vs $17.86B.